cabozantinib,belzutifan,nivolumab,tivozanib,atezolizumab
merck,roche,aveo oncology,bms
['mk6482', 'contact-3', 'belzutifan', 'nivo', 'rcc,(-irccs),(-srcc),(-urcc)', 'tinivo-2', 'cabozantinib']
#asco23 pretreated #mrcc setting w/ contact-3 trial :
- io re-challenge w/ pd-l1i ineffective - tinivo-2 results anticipated for pd-1i approach
- cabozantinib should be available after 1l io/io or io/tki - need more: pending mk6482-005 for belzutifan 
Genitourinary Cancers Disease Site Chair, @HamHealthSci | Assistant Professor, @McMasterU | Former Fellow, @DanaFarber | Focus: GU & rare cancers | Views mine